BioElectronics Announces Profitability Breakeven and Additional Clini...( As baby boomers age drug-free trea...),Health

As baby boomers age drug-free treatments receive renewed attention in

clinical trials - David G. Genecov, MD, FACS, FAAP to begin Plantar

Fasciitis Study

FREDERICK, Md., June 3 /PRNewswire-FirstCall/ -- BioElectronics Corp. (BIEL), the maker of the ActiPatch(TM), a drug free anti-inflammatory patch, with an embedded battery operated microchip delivering continuous pulse therapy, specifically designed to speed healing, today announced that recent sales successes, particularly in the international arena, and careful expense controls have resulted in the Company recently achieving operating breakeven. Additionally, the company announced today that world renowned plastic surgeon David G. Genecov will develop, institute and complete a new research study on the use of ActiPatch therapy for the treatment of plantar fasciitis, a condition that affects tens of millions of people throughout the world. The double-blind randomized study will be completed in conjunction with leading podiatrists under Dr. Genecov's direction and supervision.

"These are clearly exciting times for all of us at BioElectronics Corporation. We are continuing to see increased user acceptance of our products not only within the general and plastic surgery related markets in the United States, but also throughout many parts of Europe and Asia," commented Andy Whelan, CEO and President of BioElectronics Corporation. "Over the past few months, our international distribution channels have seen a significant amount of success and our penetration of the general and plastic surgery markets as meaningfully increased. Combined with tight expense controls at the Company, these successes have allowed us to reach profitability sooner than we had previously expected. We are expecting our revenues to continue to grow throughout the remainder of 2008 and into 2009 as ActiPatch continues to gain increased acceptance in both the domestic and international marketp
'/>"/>